The near-term PDUFA date (July 29, 2026) creates a binary catalyst. Traders should position for potential approval-driven upside, but also hedge against the risk of a Complete Response Letter. Monitor any FDA advisory committee announcements or pre-PDUFA updates.
Price Chart
Executive Summary
Outlook Therapeutics announced FDA acceptance of its resubmitted Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg) to treat wet AMD. The FDA classified the resubmission as a Class 1 review with a 60-day review period, setting a PDUFA goal date of July 29, 2026. This moves the company one step closer to potential U.S. approval for its ophthalmic bevacizumab formulation, which already has marketing authorization in the EU and UK.
Key Facts
- FDA accepted resubmitted BLA for ONS-5010 (bevacizumab-vikg) for wet AMD
- Class 1 review with 60-day review period
- PDUFA goal date set for July 29, 2026
- ONS-5010/LYTENAVA already approved in EU and UK for wet AMD
- Company has initiated pre-launch activities in anticipation of potential FDA approval
Financial Impact
Potential U.S. approval would open a large market for the first FDA-approved ophthalmic bevacizumab formulation; no financial figures provided in filing.
Risk Factors
- FDA may issue a Complete Response Letter despite Class 1 review status
- Competition from existing anti-VEGF therapies (Eylea, Lucentis, Vabysmo)
- Pricing and reimbursement uncertainties in the U.S. market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-074346 |
| Document: tm2618010d1_ex99-1.htm | 0001104659-26-074346 |
| Document: 0001104659-26-074346-index-headers.html | 0001104659-26-074346 |
| Document: 0001104659-26-074346-index.html | 0001104659-26-074346 |
| Document: 0001104659-26-074346.txt | 0001104659-26-074346 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | 424B5 | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | Press Release | $0.7564 $0.6379 | ▼ −15.67% | ▼ −13.67% | $0.5778 (−23.61%) |
Aug 13, 2026 7w ago | Press Release | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5778 (+34.99%) |
Aug 12, 2026 7w ago | 8-K | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5778 (+34.99%) |
Jul 24, 2026 9w ago | 8-K | $1.07 $0.6090 | ▼ −42.82% | ▼ −46.12% | $0.5778 (−45.75%) |
Jul 24, 2026 10w ago | Press Release | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5778 (−58.88%) |
Jul 23, 2026 10w ago | 8-K | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5778 (−58.88%) |
Jul 22, 2026 10w ago | EFFECT | $1.34 $0.6901 | ▼ −48.50% | ▼ −51.40% | $0.5778 (−56.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access